Related Experiment Video

Updated: May 16, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Mini-review: bmx kinase inhibitors for cancer therapy

John S Jarboe1, Shilpa Dutta, Sadanandan E Velu

  • 1Department of Radiation Oncology, The University of Alabama at Birmingham, 619 19th St. South, HSROC 2232C, Birmingham, AL 35249, USA.

Recent Patents on Anti-Cancer Drug Discovery
|December 4, 2012
PubMed

Insights

Bmx kinase inhibitors show promise for treating glioblastoma, prostate, breast, and lung cancers. Recent patents and literature highlight their therapeutic potential, including combination therapies and repurposing of EGFR inhibitors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Kinase inhibitors are a rapidly expanding class of anti-cancer drugs.
  • The Tec kinase family, particularly Bmx kinase, is emerging as a therapeutic target for various cancers.
  • Bmx kinase involvement is implicated in glioblastoma, prostate, breast, and lung cancer pathogenesis.

Purpose of the Study:

  • To review patents issued since 2009 detailing Bmx kinase inhibition.
  • To discuss scientific literature on the therapeutic potential of Bmx kinase inhibitors.
  • To explore Bmx kinase as a target for anti-cancer therapies, including anti-vascular and chemosensitizing applications.

Main Methods:

  • Patent literature review focusing on Bmx kinase inhibitors.
  • Scientific literature analysis of Bmx kinase's role in cancer.
  • Examination of existing EGFR inhibitors for potential Bmx kinase inhibition.

Main Results:

  • Several companies have patented Bmx kinase inhibitors.
  • Bmx kinase inhibition shows potential in preclinical cancer models.
  • Existing EGFR inhibitors may offer a route for rapid clinical development against Bmx-related malignancies.

Conclusions:

  • Bmx kinase is a validated therapeutic target for multiple cancers.
  • Patented inhibitors and repurposed EGFR inhibitors represent promising avenues for Bmx-targeted cancer therapy.
  • Further research into Bmx kinase inhibitors could lead to novel anti-cancer treatments.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...